We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications (CSSC-004)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04373460
Recruitment Status : Active, not recruiting
First Posted : May 4, 2020
Last Update Posted : June 7, 2022
State of Maryland
Bloomberg Foundation
United States Department of Defense
National Institute of Allergy and Infectious Diseases (NIAID)
National Center for Advancing Translational Sciences (NCATS)
Information provided by (Responsible Party):
Johns Hopkins University

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : January 14, 2022
Estimated Study Completion Date : September 14, 2022
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):